ľֱ

Mammo Responsibility Ups Screening; Opioids for Cancer Pain? Ignored Signs of CRC

— News, features, and commentary about cancer-related issues

MedpageToday
Onco Break over a computer rendering of a cancer cell.

Women who were more likely to complete the screening process. (Penn Medicine, American Journal of Preventive Medicine)

With the blessings of the EU and Spanish health authorities, cancer specialists at a Barcelona hospital cooked up their own , which costs a third of the marketed brands. (STAT)

Sanofi announced it will of the antibody-drug conjugate tusamitamab ravtansine following a negative outcome in a trial of second-line treatment for non-small cell lung cancer.

A trial of the radiopharmaceutical met the primary endpoint of progression-free survival, but showed an early survival trend favoring the control group, Lantheus and POINT Biopharma announced.

North Carolina has sued HCA Healthcare, alleging the for-profit system failed to keep promises to maintain consistent and high-quality following the 2019 acquisition of Mission Health System in Asheville.

The value of requires reappraisal, given "the limited quality and quantity of research," according to authors of a review. (CA: A Cancer Journal for Clinicians)

is more effective than previously recognized, according to a reanalysis of clinical trial data. (MIT News)

People who developed share their experiences and the warning signs they ignored. (NBC News)

New insights into the continuing increase in incidence and mortality, which disproportionately affects Black women. (Memorial Sloan Kettering Cancer Center)

The combination of a cancer vaccine and an immune checkpoint inhibitor reduced the risk of by 49% at 3 years. (CNBC)

Three of the first six patients with that progressed on immune checkpoint inhibition responded to an investigational tumor-infiltrating lymphocyte cellular therapy and all six had disease control, Obsidian Therapeutics announced.

  • author['full_name']

    Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined ľֱ in 2007.